

**Sysmex Europe GmbH and AdnaGen AG announced that they have entered into European distribution agreement including all current and future AdnaGen products for the detection of circulating tumor cells.**

Norderstedt and Langenhagen, Germany, – January 29, 2009 – Sysmex Europe GmbH and AdnaGen AG announced today that they have entered into a European distribution agreement for all current and future AdnaGen proprietary CE-certified diagnostics as well as the research use only (RUO) products. The tests are based on the selection of circulating tumor cells (CTC) from blood and subsequent detection and profiling of tumor markers.

Cancer diagnostics is a fast evolving and rapidly growing segment of *in-vitro* diagnostics. Following cardiovascular disorders, cancer is the second most deadly condition, affecting over 25 million people worldwide, with more than 10 million new cases diagnosed annually. Furthermore, the cost of treating cancer is putting serious pressure on healthcare budgets. Thus the need for improved diagnostics either providing an earlier diagnosis or, assisting in better therapy management is self evident.

The *AdnaTest* products for breast and colon cancer are aiming at improved cancer prognosis and patient management. The tests are based on immunomagnetic selection of tumor cells from blood followed by detection of tumor specific markers using RT-PCR amplification techniques. The advantage of the proprietary AdnaGen tests is lying in not solely detecting a single marker but, allowing the detection of a broad range of molecular biomarkers thus enabling targeted drug development. The *AdnaTest* addresses three clinical applications: Better prognosis through the identification of CTC indicative for an elevated risk of tumor metastases; detection of CTC to mirror treatment efficacy since recurrence of CTC may require prolongation of and/or alternative treatments; detection of CTC after therapy indicating a relapse or metastasis.

**About Sysmex**

Sysmex Europe GmbH is the European headquarter of Sysmex Corporation, a worldwide leading international developer and manufacturer of diagnostic, software and automation products for medical laboratories. As global market leader in the field of hematology, urinary flow cytometry and coagulation testing Sysmex has embarked on vast activities in the field of molecular cancer diagnostics. The OSNA method (one step nucleic acid amplification) for intra-operative detection of lymph node metastases in breast cancer is one example of how Sysmex contributes to patients' quality of life and cost containment within health care systems. Sysmex markets its Life Science products through an own and direct sales force in the extended European territory. For more information, please visit the Life Science website at [www.sysmex-lifescience.com](http://www.sysmex-lifescience.com)

**For further information, please contact:**

**Sysmex Europe GmbH**

Dr. Michael Schaefer

Tel: +49 (0)40 52726 0

E-Mail: [lifescience@sysmex-europe.com](mailto:lifescience@sysmex-europe.com)

[www.sysmex-lifescience.com](http://www.sysmex-lifescience.com)

**AdnaGen AG**

Dr. Wolfram Rodatz

Tel: + 49 (0)511 72595050

E-mail: [wa@adnagen.com](mailto:wa@adnagen.com)

[www.adnagen.com](http://www.adnagen.com)

**Forward-Looking Statements:** A number of statements contained in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. These risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements.